Altogether, our study revealed the critical role of a common TP53RK/Birc5 signaling pathway in promoting both p‐EMT and interstitial fibroblast proliferation during CKD development, and it established the translational potential of TP53RK and Birc5 inhibitors as therapeutic agents against CKDs. Here, TP53RK is linked to chronic kidney disease.